Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
4 search results for:

Blisibimod 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 03-04-2018 | Systemic lupus erythematosus | News | Article

    Blisibimod SLE trial fails to reach primary endpoint

    The phase III CHABLIS-SC1 trial comparing blisibimod with placebo in patients with systemic lupus erythematosus has not reached its primary endpoint of improvement in the SLE responder index at 1 year, researchers report.

    Published in:
    Ann Rheum Dis 2018; Advance online publication
  2. 03-11-2017 | Systemic lupus erythematosus | News | Article

    ADDRESS II supports further investigation of atacicept in SLE

    “These findings are consistent with subgroup analyses of blisibimod and belimumab studies that demonstrate increased treatment effect in patients with HDA,” and “suggest that when the target population is patients with HDA, there is a greater likelihood of discriminating an effective treatment from placebo,” say the authors.

    Published in:
    Arthritis Rheumatol 2017; Advance online publication
  3. 06-03-2017 | Systemic lupus erythematosus | Review | Article

    Novel treatments in lupus

    Systemic lupus erythematosus treatment has been dominated by non-specific immunosuppressive approaches. New treatments offer the potential to target the disease more specifically and are reviewed herein. Kyttaris VC. Curr Rheumatol Rep 2017;19:10. doi:10.1007/s11926-017-0638-8

  4. 10-04-2016 | Systemic lupus erythematosus | Book Chapter | Article

    Innovative therapies in systemic lupus erythematosus

    New biological agents have the potential to revolutionize the treatment of systemic lupus erythematosus. This chapter evaluates data on novel therapeutic targets that are showing promise. Fenoglio R, Fervenza F, Roccatello D. In: Connective Tissue Disease . Edited by Roccatello D & Emmi L. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-24535-5_17

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.